GLP1 & Oral Peptides Icon

Cambridge Healthtech Institute’s 13th Annual

GLP1 & Oral Peptides

Obesity-Related Drug Discovery Advances

April 15-16, 2025

 

The promise of anti-obesity therapeutics is generating a flurry of related research and drug development in the pharmaceutical and medical research establishment. In 2021, the FDA approved the first chronic weight-loss-specific medication, Wegovy, based on agonists of the glucagon-like peptide (GLP) receptor; GLP1 agonists were originally launched for diabetes. At CHI’s GLP1 & Oral Peptides conference, leading discovery chemists will convene to share progress and innovations spurred by GLP1R agonist-focused drug development, including the development of oral peptides. We also cover obesity-related therapeutic progress beyond GLP1 peptides such as the development of small molecules and 2nd generation compounds.

 

Coverage will likely include:

 

  • GLP1R peptide agonists in development
  • GLP1R small molecule agonist progress
  • Anti-obesity approaches beyond GLP1 (including dual & triple agonists)
  • Oral peptide innovations (GLP1 and beyond)
  • Peptide formulation and delivery strategies relevant to discovery chemists
  • Constrained peptide approaches for oral bioavailability

 

The deadline for submission is October 7, 2024.

 

All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

 

Opportunities for Participation:

 


For more details on the conference, please contact:

Anjani Shah, PhD

Senior Conference Director and Lead Content Director for Drug Discovery Chemistry

Cambridge Healthtech Institute

Phone: (+1) 781-247-6252

Email: ashah@healthtech.com

 

For sponsorship information, please contact:

Kristin Skahan

Senior Business Development Manager

Cambridge Healthtech Institute

Phone: (+1) 781-972-5431

Email: kskahan@healthtech.com